Medable, Masimo Partner on Wearable Devices for Clinical Research

Medable, a technology provider for modern clinical trials, began a partnership with Masimo to bring better medical-grade wearable devices to clinical research.
 
Masimo’s MightySat Rx pulse oximeter has been integrated into Medable’s evidence-generation platform for eight big-pharma-sponsored clinical trials. These trials span 25 countries, including over 3,000 patients with lung and breast cancer.
 
The duo said the device integration removes significant travel burdens and empowers patients to participate in potentially life-saving clinical trials. The partnership enables subjective data capture via Medable’s eCOA+ solution. Objective data capture is also enabled with Masimo’s connected sensors for multifaceted, deeper trial data analysis.
 
Medable said currently, 20% of trials leveraging its evidence generation platform include a wearable device. 35% of those are in oncology.
 
The company said it chose Masimo for its reputation and unique Signal Extraction Technology (SET) that provides accurate readings in challenging conditions like patient motion of low perfusion.
 
“Masimo’s SET pulse oximetry is sensitive enough to capture key vitals on the very ill like cancer patients, plus it works on all skin tones, all ages, and is easy to use,” said Musaddiq Khan, Medable’s VP of digital outcomes and TA strategy. “The Masimo team is terrific, and we look forward to long-term, collaboration so we can leverage more of their novel wearables to improve data quality and enable patients to participate in trials with less burden.”
 
“Medable has always been a leader in digital and decentralized clinical trials, so we are excited to work with a forward-thinking organization with the ambition and ability to transform research,” said Masimo chief medical officer Dr. Daniel Cantillon. “Clinical trials require top-in-class accuracy and data quality both on-site and off-site from clinical offices. Medable is solving this problem through its advocacy and by empowering more patients to participate in research. And, Medable’s flexible platform enables scalability and data aggregation for a holistic approach.”